GQ1005
HER2 low/medium Breast Cancer, Gastric Cancer, other solid tumors
Phase 1/2Active
Key Facts
Indication
HER2 low/medium Breast Cancer, Gastric Cancer, other solid tumors
Phase
Phase 1/2
Status
Active
Company
About GeneQuantum
A global leader in ADC technology, developing next-generation bioconjugate therapeutics with proprietary enzymatic conjugation platforms.
View full company profile